The limited efficacy of PD-L1 blockade is largely due to two main factors: the low immunogenicity characterized by insufficient tumor antigen release and presentation; and the “cold” immunosuppressive tumor microenvironment (TME) (Liu et al., 2023). This evidence concerns the gene CD274 and neoplasm.